New York, November 2024 – New York-founded recruitment firm Metric is proud to announce the successful placement of Rob Eyers as Chief Technology Officer at Xeltis. This appointment comes as the company also announces the completion of enrolment in EU Pivotal Trial for aXess™ and prepares for market approval.
Rob Eyers brings over three decades of in-depth experience in the cardiovascular medtech industry, in both corporate and start-up environments. He joins from Veryan Medical where he served as CTO, having previously worked for CR Bard (now Medtronic), Merit Medical, Proxy Biomedical, and Boston Scientific. He has a proven track record of taking cardiovascular implant devices through regulatory approval to commercialization.
The search was led by Metric CCO John-Joe Walker, drawing on his decade of experience as a world-leading medtech recruiter.
Of the process, Rob Eyers said: “I had the pleasure of working with John-Joe Walker during my recent recruitment process for the CTO position at Xeltis. From our very first interaction, John-Joe displayed exceptional professionalism, deep industry knowledge, and a genuine commitment to ensuring a seamless recruitment experience.”
Rob joins Xeltis during an exciting period of innovation as they announce the completion of enrolment in its EU Pivotal trial for aXess™, its restorative vascular access conduit, in adults with end-stage renal disease.
Speaking of the placement, Metric CCO John-Joe Walker added: “Having worked with Xeltis to place a variety of roles over the years, it was a pleasure to facilitate the appointment of Rob as their CTO during such an exciting time of the company’s growth. Rob’s extensive knowledge and experience in the sector will undoubtedly have a huge impact on Xeltis as they continue to bring innovative and transformative solutions to market.”
